NCT03316820 is a Phase 1 clinical trial of K0706 in Healthy, sponsored by Sun Pharma Advanced Research Company Limited.

Who is sponsoring NCT03316820?

NCT03316820 is sponsored by Sun Pharma Advanced Research Company Limited.

What drugs are being tested in NCT03316820?

Interventions in NCT03316820: K0706, K0706.

Is NCT03316820 still recruiting?

NCT03316820 is currently completed. Last updated 3 May 2019.

Last reviewed 2019-05-03 · How we verify

NCT03316820

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bioavailability Study of K0706 in Healthy Subjects

Completed Phase 1 Last updated 3 May 2019

What this trial tests

Phase 1 trial testing K0706 in Healthy in 24 participants. Completed in 21 November 2017.

Timeline

28 October 2017

Primary endpoint
21 November 2017

21 November 2017

Quick facts

Lead sponsor	Sun Pharma Advanced Research Company Limited
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	28 October 2017
Primary completion	21 November 2017
Estimated completion	21 November 2017
Sites	1 location across United States

Drugs / interventions tested

K0706 — full drug profile →
K0706 — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Sun Pharma Advanced Research Company Limited — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is single-center, single-dose, randomized, open-label, four-period, four sequence crossover study to evaluate the relative bioavailability of K0706 24 mg tablet formulation relative to 24 mg capsule formulation under fasted conditions and to evaluate the food-effect for tablet formulation in healthy subjects.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Therapeutics in the Pipeline Targeting <i>α</i>-Synuclein for Parkinson's Disease.
Grosso Jasutkar H, Oh SE, Mouradian MM. · · 2022 · cited 69× · PMID 35017177 · DOI 10.1124/pharmrev.120.000133
Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity.
Werner MH, Olanow CW. · · 2022 · cited 46× · PMID 34816484 · DOI 10.1002/mds.28858
Alpha synuclein post translational modifications: potential targets for Parkinson's disease therapy?
Brembati V, Faustini G, Longhena F, Bellucci A. · · 2023 · cited 27× · PMID 37305556 · DOI 10.3389/fnmol.2023.1197853
Novel approaches to counter protein aggregation pathology in Parkinson's disease.
Stott SRW, Wyse RK, Brundin P. · · 2020 · cited 7× · PMID 32247372 · DOI 10.1016/bs.pbr.2019.10.007

Verify or expand the search:

Other trials of K0706

Trials testing the same drug.

NCT03655236 — PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase · Phase 2 · terminated
NCT03445338 — To Evaluate the Safety, Tolerability and Pharmacokinetics of K0706 in Plasma and Cerebrospinal Fluid in Healthy Voluntee · Phase 1 · completed
NCT02970019 — Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease · Phase 1 · completed
NCT07517315 — Expanded Access to Vodobatinib for Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Not · temporarily not available

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Sun Pharma Advanced Research Company Limited trials

Trials by the same sponsor.

NCT04942054 — A Study in Patients With Advanced Breast Cancer · Phase 1 · terminated
NCT04332549 — To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Rec · Phase 1 · withdrawn
NCT04242953 — Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subj · Phase 1 · completed
NCT03655236 — PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase · Phase 2 · terminated
NCT02597465 — A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507 · Phase 3 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03316820 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Pharma Advanced Research Company Limited
Last refreshed: 3 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03316820.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing